Aktieanalys

Genovis Q4 2022: A First Sublicensing of Xork - Redeye

{newsItem.title}

Redeye Publicerad: 16 Feb 2023 10:53

Redeye returns with an updated take on the pick-and-shovel play Genovis following its partner Selecta Biosciences’ licensing deal with Astellas Pharma and the company’s Q4 2022 report. With reinforced confidence in the deal with Selecta, we have raised our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/878440/genovis-q4-2022-a-first-sublicensing-of-xork?utm_source=finwire&utm_medium=RSS

Nyheter om Genovis

Läses av andra just nu

Om aktien Genovis

Senaste nytt